| Basics |
Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer.
|
| IPO Date: |
April 28, 2017 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$1.14B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.46 | 2.62%
|
| Avg Daily Range (30 D): |
$0.30 | 2.17%
|
| Avg Daily Range (90 D): |
$0.27 | 2.10%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.43M |
| Avg Daily Volume (30 D): |
.36M |
| Avg Daily Volume (90 D): |
.34M |
| Trade Size |
| Avg Trade Size (Sh.): |
103 |
| Avg Trade Size (Sh.) (30 D): |
59 |
| Avg Trade Size (Sh.) (90 D): |
57 |
| Institutional Trades |
| Total Inst.Trades: |
1,503 |
| Avg Inst. Trade: |
$1.72M |
| Avg Inst. Trade (30 D): |
$1.18M |
| Avg Inst. Trade (90 D): |
$1.25M |
| Avg Inst. Trade Volume: |
.12M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.31M |
| Avg Closing Trade (30 D): |
$.85M |
| Avg Closing Trade (90 D): |
$1.09M |
| Avg Closing Volume: |
103.35K |
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$.03
|
$-.3
|
$-.32
|
|
Diluted EPS
|
$.03
|
$-.3
|
$-.32
|
|
Revenue
|
$ 48.73M
|
$ 27.11M
|
$ 31.03M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ 2.32M
|
$ -22.64M
|
$ -23.51M
|
|
Operating Income / Loss
|
$ -.67M
|
$ -25.61M
|
$ -22.22M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ 22.05M
|
$ 10.1M
|
$ -56.25M
|
|
PE Ratio
|
509.33
|
|
|
|
|
|
